Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoLife's cardiac patch approved in US

This article was originally published in Clinica

Executive Summary

The CryoPatch SG pulmonary human cardiac patch developed by CryoLife has received 510(k) clearance from the US FDA for the repair of the right ventricular outflow tract. This surgery is commonly performed in children with congenital heart defects – a market worth $15m in the US. Launch is set for the third quarter of 2009. The patch is produced using the Kennesaw, Georgia company's SynerGraft technology, which removes allogeneic donor cells and cellular remnants from donated tissue, avoiding immunological rejection.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel